In designing pharmaceutical manufacturing alongside the principles of quality by design (QbD) and process analytical technology (PAT), unit operations process development and corporate decision-making processes such as business profits and environmental impact assessments are often undertaken separately. This paper presents a strategic three-tier framework linking the process, operations, and business/enterprise levels for process development and improvement alongside an in silico optimization approach.